We suggest that high levels of TGFB2 combined with low levels of IFNGR2 are strong prognostic markers for worse overall survival outcomes and that abrogating TGFB2 levels in tumors with low levels of IFNGR2 in anti-tumor immune cells is a feasible strategy to improve overall survival in pbDMG patients. This evidence concerns the gene IFNGR2 and neoplasm.